Outlook Therapeutics (OTLK) Price & Analysis

Compare

1,527 Followers

OTLK Stock Chart & Stats

$1.80

-$0.17(-7.61%)

At close: Jan 08 4:00 PM EST

$1.80

-$0.17(-7.61%)

Day’s Range― - ―

52-Week Range$0.79 - $5.15

Previous CloseN/A

Volume358.39K

Average Volume (3M)3.57M

Market Cap

$79.96M

Enterprise Value$84.93M

Total Cash (Recent Filing)$8.90M

Total Debt (Recent Filing)$34.70M

Price to Earnings (P/E)―

Beta0.75

Next Earnings

Dec 18, 2025

EPS Estimate

-0.26

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.44

Shares Outstanding44,419,530

10 Day Avg. Volume8,294,051

30 Day Avg. Volume3,573,866

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)-1.36

Price to Sales (P/S)0.00

P/FCF Ratio-1.44

Enterprise Value/Market Cap1.06

Enterprise Value/Revenue50.69

Enterprise Value/Gross Profit77.72

Enterprise Value/Ebitda-1.76

Forecast

1Y Price Target

$4.00

Price Target Upside122.22% Upside

Rating ConsensusHold

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Commercial FocusThe commercialization of Lytenava (ONS-5010) in Europe, particularly Germany, is the company's focus.

European LaunchThe focus is expected to shift to the ongoing European launch, which is in the early stages, while pricing negotiations continue.

Market ExpansionExpansion into other European countries, starting in Austria and the Netherlands, could drive further growth.

Bears Say

Development RiskONS-5010 is the company's sole active development program, presenting a risk if it fails.

Financial StabilityFinancing continues to be a major overhang on the name; with cash guidance only for the next 3 months, there are serious doubts on the company's ability to get ONS-5010 approved in the U.S.

Regulatory ChallengesThe FDA issued a CRL for the BLA resubmission of ONS-5010 in wet AMD, requiring additional evidence of efficacy for approval.

Outlook Therapeutics News

Outlook Therapeutics announces acceptance of BLA for ONS-5010

Outlook Therapeutics (OTLK) announced that the U.S. Food and Drug Administration, FDA, has acknowledged receipt of the resubmission...

13d ago

OTLK

Outlook Therapeutics resubmits BLA for ONS-5010

Outlook Therapeutics (OTLK) announced it has re-submitted its Biologics License Application, BLA, to the U.S. Food and Drug...

23d ago

OTLK

Outlook Therapeutics’ FDA Review for ONS-5010 Resubmission

An update from Outlook Therapeutics ( ($OTLK) ) is now available. On November 13, 2025, Outlook Therapeutics announced...

13d ago

OTLK

Outlook Therapeutics Resubmits Biologics License Application

Outlook Therapeutics ( ($OTLK) ) just unveiled an announcement. On November 3, 2025, Outlook Therapeutics announced the resubmission...

23d ago

OTLK

Outlook Therapeutics: Hold Rating Amid Uncertainties in BLA Resubmission and Market Challenges

Analyst Douglas Tsao from H.C. Wainwright reiterated a Hold rating on Outlook Therapeutics and keeping the price target...

2M ago

OTLK

Outlook Therapeutics Completes FDA Meeting on ONS-5010

Outlook Therapeutics ( ($OTLK) ) just unveiled an announcement. On September 29, 2025, Outlook Therapeutics announced the completion...

2M ago

OTLK

Outlook Therapeutics says plans to resubmit BLA before end of CY25

Outlook Therapeutics (OTLK) announced that it has completed the Type A Meeting with the U.S. Food and Drug...

2M ago

OTLK

Outlook Therapeutics says had ‘productive’ discussion with FDA

08:46 EDT Outlook Therapeutics (OTLK) says had ‘productive’ discussion with FDA Published first on TheFly – the ultimate...

2M ago

OTLK

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: CEA Industries Inc (BNC)...

2M ago

BNC

MBX

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Outlook Therapeutics Inc (OTLK)...

2M ago

RDW

KYIV

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Outlook Therapeutics Inc (OTLK)...

3M ago

RDW

BULL

Outlook Therapeutics CCO Jeff Evanson Steps Down

Outlook Therapeutics ( ($OTLK) ) has provided an announcement. On September 5, 2025, Jeff Evanson stepped down as...

3M ago

OTLK

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Outlook Therapeutics Inc (OTLK)...

3M ago

LIT

FDA Issues Complete Response Letter to Outlook Therapeutics

Outlook Therapeutics ( ($OTLK) ) has issued an update. On August 28, 2025, Outlook Therapeutics announced that the...

3M ago

OTLK

OTLK FAQ

What was Outlook Therapeutics’s price range in the past 12 months?

Outlook Therapeutics lowest stock price was $0.79 and its highest was $5.15 in the past 12 months.

What is Outlook Therapeutics’s market cap?

Outlook Therapeutics’s market cap is $79.96M.

When is Outlook Therapeutics’s upcoming earnings report date?

Outlook Therapeutics’s upcoming earnings report date is Dec 18, 2025 which is in 22 days.

How were Outlook Therapeutics’s earnings last quarter?

Outlook Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.352 by -$0.088.

Is Outlook Therapeutics overvalued?

According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Outlook Therapeutics pay dividends?

Outlook Therapeutics does not currently pay dividends.

What is Outlook Therapeutics’s EPS estimate?

Outlook Therapeutics’s EPS estimate is -0.26.

How many shares outstanding does Outlook Therapeutics have?

Outlook Therapeutics has 44,419,530 shares outstanding.

What happened to Outlook Therapeutics’s price movement after its last earnings report?

Outlook Therapeutics reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.352. Following the earnings report the stock price went up 14.085%.

Which hedge fund is a major shareholder of Outlook Therapeutics?

Currently, no hedge funds are holding shares in OTLK

Outlook Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-52.45%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Outlook Therapeutics

Outlook Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody therapies. The company is primarily engaged in the research and development of therapeutics in the field of ophthalmology. Its leading product candidate is ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation designed for use in treating wet age-related macular degeneration (AMD) and other retinal diseases.

Outlook Therapeutics (OTLK) Earnings & Revenues

Historic Earnings Reports

OTLK Stock 12 Month Forecast

Average Price Target

$4.00

▲(122.22% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.26,1.7784615384615385,2.2969230769230773,2.8153846153846156,3.333846153846154,3.8523076923076927,4.370769230769231,4.889230769230769,5.407692307692308,5.926153846153847,6.4446153846153855,6.963076923076923,7.481538461538462,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.26,1.4707692307692308,1.6815384615384616,1.8923076923076922,2.103076923076923,2.313846153846154,2.5246153846153847,2.7353846153846155,2.9461538461538463,3.156923076923077,3.367692307692308,3.5784615384615384,3.7892307692307696,{"y":4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.26,1.24,1.22,1.2,1.18,1.16,1.1400000000000001,1.12,1.1,1.08,1.06,1.04,1.02,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.41,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.35,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.22,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.03,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.89,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >